
        <!DOCTYPE html>
    <html lang="ja">
    <style>
    body
    {
        color: black;
        background-color: white;
    }
    div{
        font-size: 14px;
    }
    span
    {
        font-size: 18px;
    }
    #grad1{
        background: linear-gradient(transparent 60%,#99e4f1 30%);
        font-size: 18px;
        font-weight: bold;
    }
    #grad2{
        background: linear-gradient(transparent 60%,#fda1a1 30%);
        font-size: 18px;
        font-weight: bold;
    }

    </style>

    <head>
        <meta charset="UTF-8">
        <title>105-266</title>
    </head>

    <body>
        <h1>
        <a href="./105_265.html" rel="external" title="prev">≪</a>
        105-266
        <a href="./105_267.html" rel="external" title="next">≫</a>
        </h1>
        <div class='problem'>
            <p>
                <span id="grad1">　問題文　</span>
            </p>
            <p>
                <p>68歳男性。狭心症。かかりつけ医を受診し、定期的に処方1の薬剤を服用している。来局時の聞き取りにより、この患者は最近、他の医療機関で非小細胞肺がんと診断され、エルロチニブ塩酸塩錠による化学療法の実施が予定されているとのことであった。</p>
<p><img alt="" class="alignnone size-full wp-image-21177" height="142.79999999999998" loading="lazy" sizes="(max-width: 633px) 100vw, 633px" src="data:;base64,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" width="443.09999999999997"/></p>
<h4>問266</h4>
<p>薬剤師は、かかりつけ医に化学療法に関する聞き取りの内容を伝え、処方変更について提案した。その内容として最も適切なのはどれか。1つ選べ。</p>
<ol><li>アスピリン腸溶錠を中止する。</li><li>エソメプラゾールマグネシウム水和物カプセルを中止する。</li><li>エソメプラゾールマグネシウム水和物カプセルをラニチジン錠に変更する。</li><li>ビソプロロールフマル酸塩錠を中止する。</li><li>ビソプロロールフマル酸塩錠をベラパミル塩酸塩錠に変更する。</li></ol>
<h4>問267</h4>
<p>処方変更をしない場合に問題となる、エルロチニブの体内動態の変化として適切なのはどれか。1つ選べ。</p>
<ol><li>吸収の低下</li><li>肝代謝の阻害</li><li>肝代謝の亢進</li><li>尿中排泄の阻害</li><li>胆汁排泄の阻害</li></ol>    
            </p>
        </div>
        <hr>

        <input type="button" value="check ans" onclick="toggle_switch()"/>
        
        <div id='toggle'>
        <div class='answer'>
            <p>
                <span id="grad2">　解答　　</span>
            </p>
            <p>
            問266：2問267：1
            </p>
        </div>
        <div class='description'>
            <p>
                <span id="grad2">　解説　　</span>
            </p>
            <h4>問266</h4>
<p>問 267 と合わせて解説します。</p>
<h4>問267</h4>
<p>エルロチニブ（®タルセバ）は、EGFR チロシンキナーゼ阻害薬の一種です。PPI や H<span style="font-weight: 400;"><sub>2</sub></span> 受容体拮抗薬との併用により、胃酸 pH が持続的上昇 → AUC 低下 が知られています。</p>
<p>以上より<br/>問 266 の正解は 2 です。<br/>問 267 の正解は 1 です。</p>
            </p>
        </div>
        </div>
    </body>
    <script>
    document.getElementById("toggle").style.display="none";
    function toggle_switch(){
        var x = document.getElementById("toggle");
        if (x.style.display=="block"){
            x.style.display="none";
        }
        else{
            x.style.display="block";
        }
    }
    </script>
    